Results 251 to 260 of about 10,900 (261)

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

Current Medical Research and Opinion, 2008
Krista L Lanctôt, Jean-Eric Tarride, Bosco A Paes   +2 more
exaly  

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

Journal of Clinical Virology, 2008
Guy Boivin, Julie Carbonneau
exaly  

Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients

Journal of Infectious Diseases, 2018
Xunyan Ye, Vasanthi Avadhanula, Felipe-Andres Piedra   +2 more
exaly  

Palivizumab Prophylaxis and Recurrent Wheezing

American Journal of Respiratory and Critical Care Medicine, 2018
openaire   +2 more sources

Palivizumab prophylaxis in preterm infants

The Lancet Respiratory Medicine, 2017
openaire   +2 more sources

PALIPERIDONE PALIVIZUMAB

2014
openaire   +1 more source

Life Years Gained From Palivizumab

Pediatric Infectious Disease Journal, 2012
openaire   +2 more sources

Palivizumab (r)

2011
openaire   +1 more source

Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective

Journal of Medical Economics, 2012
exaly  

Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States

Journal of Medical Economics, 2012
exaly